Maxigen Biotech Inc (1783) - Net Assets
Based on the latest financial reports, Maxigen Biotech Inc (1783) has net assets worth NT$1.63 Billion TWD (≈ $51.25 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.99 Billion ≈ $62.72 Million USD) and total liabilities (NT$364.27 Million ≈ $11.48 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 1783 total asset value for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.63 Billion |
| % of Total Assets | 81.7% |
| Annual Growth Rate | 10.46% |
| 5-Year Change | 34.67% |
| 10-Year Change | 96.78% |
| Growth Volatility | 31.97 |
Maxigen Biotech Inc - Net Assets Trend (2009–2025)
This chart illustrates how Maxigen Biotech Inc's net assets have evolved over time, based on quarterly financial data. Check 1783 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Maxigen Biotech Inc (2009–2025)
The table below shows the annual net assets of Maxigen Biotech Inc from 2009 to 2025. For live valuation and market cap data, see 1783 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.54 Billion ≈ $48.44 Million |
+11.82% |
| 2024-12-31 | NT$1.38 Billion ≈ $43.32 Million |
+1.03% |
| 2023-12-31 | NT$1.36 Billion ≈ $42.88 Million |
+5.05% |
| 2022-12-31 | NT$1.30 Billion ≈ $40.82 Million |
+13.48% |
| 2021-12-31 | NT$1.14 Billion ≈ $35.97 Million |
+32.72% |
| 2020-12-31 | NT$860.23 Million ≈ $27.10 Million |
+1.05% |
| 2019-12-31 | NT$851.32 Million ≈ $26.82 Million |
+0.99% |
| 2018-12-31 | NT$842.98 Million ≈ $26.56 Million |
+5.87% |
| 2017-12-31 | NT$796.25 Million ≈ $25.09 Million |
+1.90% |
| 2016-12-31 | NT$781.38 Million ≈ $24.62 Million |
-5.84% |
| 2015-12-31 | NT$829.86 Million ≈ $26.14 Million |
-5.38% |
| 2014-12-31 | NT$877.01 Million ≈ $27.63 Million |
-1.28% |
| 2013-12-31 | NT$888.39 Million ≈ $27.99 Million |
+130.36% |
| 2012-12-31 | NT$385.66 Million ≈ $12.15 Million |
+4.44% |
| 2011-12-31 | NT$369.25 Million ≈ $11.63 Million |
-6.61% |
| 2010-12-31 | NT$395.39 Million ≈ $12.46 Million |
+26.31% |
| 2009-12-31 | NT$313.03 Million ≈ $9.86 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Maxigen Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 44877000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$265.04 Million | 17.24% |
| Common Stock | NT$896.88 Million | 58.33% |
| Other Components | NT$375.67 Million | 24.43% |
| Total Equity | NT$1.54 Billion | 100.00% |
Maxigen Biotech Inc Competitors by Market Cap
The table below lists competitors of Maxigen Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kirana Megatara Tbk PT
JK:KMTR
|
$112.64 Million |
|
X Financial Class A
NYSE:XYF
|
$112.65 Million |
|
Scottie Resources Corp
V:SCOT
|
$112.67 Million |
|
OPTIMIZERx Corp
NASDAQ:OPRX
|
$112.78 Million |
|
YFC-BonEagle Electric Co Ltd
TWO:6220
|
$112.59 Million |
|
General de Alquiler de Maquinaria SA
MC:GAM
|
$112.58 Million |
|
Wallbridge Mining Company Limited
TO:WM
|
$112.57 Million |
|
Reward Wool Industry Corp
TW:1423
|
$112.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Maxigen Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,375,127,000 to 1,537,599,000, a change of 162,472,000 (11.8%).
- Net income of 265,312,000 contributed positively to equity growth.
- Dividend payments of 74,431,000 reduced retained earnings.
- New share issuances of 393,000 increased equity.
- Other factors decreased equity by 28,802,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$265.31 Million | +17.25% |
| Dividends Paid | NT$74.43 Million | -4.84% |
| Share Issuances | NT$393.00K | +0.03% |
| Other Changes | NT$-28.80 Million | -1.87% |
| Total Change | NT$- | 11.82% |
Book Value vs Market Value Analysis
This analysis compares Maxigen Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.76x to 2.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$6.92 | NT$39.85 | x |
| 2010-12-31 | NT$7.25 | NT$39.85 | x |
| 2011-12-31 | NT$6.69 | NT$39.85 | x |
| 2012-12-31 | NT$6.77 | NT$39.85 | x |
| 2013-12-31 | NT$13.26 | NT$39.85 | x |
| 2014-12-31 | NT$11.37 | NT$39.85 | x |
| 2015-12-31 | NT$10.67 | NT$39.85 | x |
| 2016-12-31 | NT$10.18 | NT$39.85 | x |
| 2017-12-31 | NT$10.41 | NT$39.85 | x |
| 2018-12-31 | NT$9.88 | NT$39.85 | x |
| 2019-12-31 | NT$9.69 | NT$39.85 | x |
| 2020-12-31 | NT$10.67 | NT$39.85 | x |
| 2021-12-31 | NT$13.58 | NT$39.85 | x |
| 2022-12-31 | NT$14.49 | NT$39.85 | x |
| 2023-12-31 | NT$15.22 | NT$39.85 | x |
| 2024-12-31 | NT$15.33 | NT$39.85 | x |
| 2025-12-31 | NT$17.15 | NT$39.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Maxigen Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.25%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 32.69%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.23x
- Recent ROE (17.25%) is above the historical average (3.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 4.03% | 6.99% | 0.53x | 1.10x | NT$-18.68 Million |
| 2010 | -4.05% | -9.28% | 0.40x | 1.09x | NT$-55.54 Million |
| 2011 | -9.77% | -20.17% | 0.37x | 1.32x | NT$-73.00 Million |
| 2012 | 0.72% | 1.25% | 0.44x | 1.31x | NT$-35.80 Million |
| 2013 | 0.29% | 1.11% | 0.23x | 1.14x | NT$-86.26 Million |
| 2014 | -2.17% | -7.75% | 0.24x | 1.16x | NT$-106.74 Million |
| 2015 | -7.59% | -24.08% | 0.22x | 1.41x | NT$-145.94 Million |
| 2016 | -1.57% | -3.64% | 0.31x | 1.40x | NT$-90.38 Million |
| 2017 | 1.98% | 3.69% | 0.39x | 1.39x | NT$-63.84 Million |
| 2018 | 6.77% | 13.34% | 0.38x | 1.35x | NT$-27.24 Million |
| 2019 | 7.06% | 13.29% | 0.38x | 1.39x | NT$-25.02 Million |
| 2020 | 7.36% | 13.83% | 0.48x | 1.11x | NT$-22.71 Million |
| 2021 | 7.68% | 17.12% | 0.40x | 1.11x | NT$-26.50 Million |
| 2022 | 10.76% | 23.06% | 0.42x | 1.12x | NT$9.84 Million |
| 2023 | 12.18% | 26.66% | 0.42x | 1.10x | NT$29.72 Million |
| 2024 | 13.83% | 27.94% | 0.43x | 1.15x | NT$52.65 Million |
| 2025 | 17.25% | 32.69% | 0.43x | 1.23x | NT$111.55 Million |
Industry Comparison
This section compares Maxigen Biotech Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,856,137,667
- Average return on equity (ROE) among peers: 16.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Maxigen Biotech Inc (1783) | NT$1.63 Billion | 4.03% | 0.22x | $112.59 Million |
| St.Shine Optical Co Ltd (1565) | $3.89 Billion | 41.14% | 0.59x | $146.13 Million |
| SciVision Biotech Inc (1786) | $1.08 Billion | 3.72% | 0.04x | $116.46 Million |
| Bioteque (4107) | $1.62 Billion | 13.32% | 0.24x | $247.80 Million |
| Chi Sheng Chemical (4111) | $1.05 Billion | 7.76% | 0.41x | $56.27 Million |
| BenQ Medical Technology (4116) | $1.09 Billion | 6.10% | 0.54x | $54.27 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.55 Billion | 17.99% | 0.55x | $173.61 Million |
| Bionime Corp (4737) | $1.09 Billion | 16.51% | 1.63x | $136.35 Million |
| Vizionfocus Inc. (4771) | $2.04 Billion | 27.62% | 1.19x | $336.64 Million |
| Formosa Optical Technology Co Ltd (5312) | $2.30 Billion | 15.61% | 0.85x | $168.03 Million |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, d… Read more